Global Preeclampsia Diagnostics Market Size Likely to Grow at a CAGR of 3.3% By 2035

To drive the growth of the market, the global Preeclampsia Diagnostics market is projected to grow to about USD 1.15 billion as early as 2025, and is expected to grow to an even higher level of close to USD 1.19 billion by 2026, and to continue its growth to approximately USD 1.59 billion by 2035 with a CAGR of 3.3% over the next 10 year forecast of 2026-2035.

Preeclampsia diagnostics market Revenue and Trends

The market of Preeclampsia Diagnostics is a critical market segment of the greater industry of maternal and prenatal care, as it facilitates the identification and monitoring of hypertensive conditions in the course of pregnancy and avoids extreme maternal and fetal complications. The market is experiencing a gradual growth owing to the growing rate of high-risk pregnancies, growing awareness about maternal health as well as the growing significance of early screening and preventive care.

The latest innovations in diagnostic technologies, such as biomarker-based tests, non-invasive diagnostic procedures, and digital health monitoring systems, are changing the situation greatly, enhancing the first-time diagnosis and patient outcomes. Moreover, healthy growth of the healthcare infrastructure, growing investments in prenatal care services and the favorable government programs in areas like Asia Pacific, North America and Europe are also growing in markets. The accessibility and efficiency is also being improved by continuous innovation of the point-of-care diagnostics and remote monitoring tools that will facilitate the long-term evolution of the market.

What are the Factors that Substantially Contribute to the Development of the Preeclampsia diagnostics market?

Preeclampsia Diagnostics market is mainly developed due to the growing demand of early, precise, and timely detection of pregnancy-related hypertensive disorders in the world. The increasing cases of high-risk pregnancies and the increased focus on maternal and fetal health have greatly contributed to the increased need to seek dependable diagnostic solutions. Clinical decision-making and patient outcomes are being improved by the use of the latest diagnostic methods that include biomarker-based testing, non-invasive screening techniques, and continuous blood pressure monitoring. Furthermore, the increasing attention to preventive care and regular prenatal check-ups is contributing to the swift adoption of these diagnostics into the routine of the clinical practices in hospitals and other maternity centers.

The market is also maintained by the technological progress and necessity to standardize and make diagnostic processes effective. Improved accessibility to maternal health parameters and real-time monitoring of the maternal health parameters is occurring due to innovations in point-of-care testing, digital health, and remote monitoring solutions. Meanwhile, the tendency to transition to individualized prenatal care is pushing the need to single out more accurate and predictive diagnostic instruments. The long-term growth of the market is attributed to the expansion of healthcare infrastructure, the growing investments in the sphere of maternal healthcare services, and supportive measures of the state governments oriented on the decrease of maternal mortality, and the constant improvement of diagnostic technologies guaranteed the better accuracy, convenience, and scalability.

Segment Insight

By Test Type

Tests based on biomarkers dominate the Preeclampsia Diagnostics market because they can be used to respond with early and accurate diagnosis of the disease contributing to timely clinical treatment and better maternal-fetal outcomes. Blood pressure measurement is a traditional method of diagnosis because hypertension is one of the main predictors, and the use of digital and wearable devices is becoming more common in ensuring continuous monitoring. Urine analysis kits will remain an important part of standard screening since they can be used to identify proteinuria, particularly in low-resource countries because they are inexpensive and do not require complex handling. Imaging methods are becoming significant in order to have a more detailed evaluation of fetal development and placental functioning as a way of managing high-risk pregnancies.

By Application

The market is partly controlled by early screening which is required to detect the threat of preeclampsia at the first stage of the disease and avoid serious complications. Risk assessment is also expanding at a high rate due to the application of sophisticated diagnostic equipment and biomarkers to rank the patients according to the severity. One of the most important segments, which is motivated by the necessity to constantly supervise high-risk pregnancies, is maternal health monitoring under the support of digital and remote monitoring solutions. The field of fetal health assessment is also growing because of the growing attention to the insured healthy childbirth and decreased pregnancy risks.

By End-User

The hospitals command the highest portion of the market because of the sophisticated diagnostic facilities and the increased traffic of patients seeking prenatal services and pregnant women in the management of high risk pregnancies. The adoption of special diagnostic tools related to routine check-ups and early diagnoses is on the rise in maternity clinics. Diagnostic labs have a major role in carrying out advanced tests based on biomarkers and aid in the case of in-vitro screening programs. The home care environment is developing gradually in line with the introduction of remote monitoring tools and the increased popularity of constant at-home monitoring of maternal health.

By Region

North America is dominating the market because it has well developed healthcare systems, high awareness, and has embraced the use of the advanced prenatal diagnostics at an earlier age. Europe comes behind with stable growth with well-organized prenatal care schemes and robust control policies. The region that is growing fastest is Asia-Pacific due to the increasing birth rates, advancement in healthcare facilities and the creation of awareness in the countries like China and India. The growth in Latin America and the Middle East and Africa is also slowing with the access to better healthcare services, the increase on investments in the maternal care, and the attention to the early detection of complications related to pregnancy.

Report Scope

Recent Developments

• Danaher Corporation announced improvements to its diagnostics business through built-in clinical testing platforms in April 2024 to aid this company in enhancing maternal health diagnostics and workflow efficiency.

List of the prominent players in the Preeclampsia Diagnostics Market:

• Roche Diagnostics

• Abbott Laboratories

• Siemens Healthineers

• GE HealthCare

• Thermo Fisher Scientific

• PerkinElmer

• Danaher Corporation

• bioMérieux

• QuidelOrtho Corporation

• Becton Dickinson and Company

• Hologic Inc.

• F. Hoffmann-La Roche Ltd.

• Others

The Preeclampsia Diagnostics Market is segmented as follows:

By Test Type

• Biomarker-Based Tests

• Blood Pressure Monitoring

• Urine Analysis Kits

• Imaging Techniques

By Application

• Early Screening

• Risk Assessment

• Maternal Health Monitoring

• Fetal Health Evaluation

By End-User

• Hospitals

• Maternity Clinics

• Diagnostic Laboratories

• Home Care Settings

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America